Expect 'New Insights and Complexity' in Multiple Sclerosis

Stephen Krieger, MD


October 12, 2018

Hi. I'm Dr Stephen Krieger from Mount Sinai in New York. I'm here at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) conference, being held in Berlin, Germany, this year. This is an international gathering of researchers, clinicians, scientists, and industry folks all looking at MS. ECTRIMS has a number of themes this year. I expect that we will see new data and insights on the pathogenesis of MS, and some new insights into pathology and the grey and white matter disease processes that inform clinical course. I think we'll also see new complexity in how our clinical trials are being designed in MS, including the development of adaptive trial design. It's a little different from the stepwise incremental approach that we've taken to clinical trials in recent years. Furthermore, I think we'll see new insights and complexity in our understanding of prognostic factors in MS; neurofilament light is one of the most interesting emerging biomarkers in this disease. Finally, cognition remains a hot topic, and I think we'll see even more complexity and nuance in how we understand cognitive dysfunction in MS.

I look forward to bringing you updates in MS in the coming days from ECTRIMS 2018 in Berlin, Germany.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.